BRIDGEWATER, N.J.—RVL Pharmaceuticals said its FDA-approved acquired blepharoptosis (ptosis) drug Upneeq (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected as the winner of a “Best in Innovation” award in the 12th Annual Beauty Awards conducted by New Beauty, a Sandow Publication. In a record-breaking year of product introductions, over 10,000 products were submitted and tested by the editorial team of New Beauty and an independent group of medical and industry professionals, according to RVL’s recent announcement.

Upneeq was dubbed a Best in Innovation product for 2022 and “The Best Secret for Wide Awake Eyes” by the industry and consumer publication. New Beauty, a trend-driven education-powered quarterly published resource and website, has been a leader in the aesthetic space since its launch in 2005. The top 365 products were selected in a range of categories for illustrious awards.

Upneeq is a safe and effective, first-in-class treatment for acquired ptosis, providing patients, eyecare professionals and all aesthetic providers a simple, convenient daily drop as of the national roll-out in January 2022, RVL said.

New Beauty said Upneeq, a non-surgical option to treat adults with acquired ptosis, “is an instant eye-lifter for adults with acquired ptosis or low-lying eyelids. It's a true aesthetic innovation unlike anything else on the market.”

“We are thrilled to be acknowledged by New Beauty with an Innovation Award for Upneeq,” added J.D. Schaub, EVP and chief operating officer at RVL. “We have full confidence that Upneeq, which is unmatched and emerging in the aesthetic marketplace, has the potential to address the significant unmet need in acquired ptosis therapy. Industry support and validation like this award from New Beauty is further proof of concept.”

Upneeq, which is composed of oxymetazoline hydrochloride ophthalmic solution at 0.1%, received its final FDA approval in July 2020, introducing to the market the only non-surgical therapeutic approved for the condition.